Connecticut 2017 Regular Session

Connecticut Senate Bill SB00545 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 General Assembly Proposed Bill No. 545
22 January Session, 2017 LCO No. 2990
33 *02990*
44 Referred to Committee on INSURANCE AND REAL ESTATE
55 Introduced by:
66 SEN. KENNEDY, 12th Dist.
77
88 General Assembly
99
1010 Proposed Bill No. 545
1111
1212 January Session, 2017
1313
1414 LCO No. 2990
1515
1616 *02990*
1717
1818 Referred to Committee on INSURANCE AND REAL ESTATE
1919
2020 Introduced by:
2121
2222 SEN. KENNEDY, 12th Dist.
2323
2424 AN ACT CONCERNING A STUDY OF REQUESTS BY HEALTH CARE PROVIDERS TO OVERRIDE STEP THERAPY DRUG REGIMENS FOR CERTAIN CANCER PATIENTS.
2525
2626 Be it enacted by the Senate and House of Representatives in General Assembly convened:
2727
2828 That the Insurance Commissioner shall study and report on (1) the processes that insurance companies, hospital service corporations, medical service corporations, health care centers and other entities that use step therapy for prescription drugs employ in assessing requests made by treating health care providers to override the use of step therapy drug regimens for insureds diagnosed with metastatic cancer, and (2) the response time to such requests.
2929
3030 Statement of Purpose:
3131
3232 To require a study and report on the processes that insurance companies, hospital service corporations, medical service corporations, health care centers and other entities that use step therapy for prescription drugs employ in assessing requests made by treating health care providers to override the use of step therapy drug regimens for insureds diagnosed with metastatic cancer and the response time to such requests.